Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 4;12(1):125.
doi: 10.1186/s13023-017-0678-1.

Phenotype prediction for mucopolysaccharidosis type I by in silico analysis

Affiliations

Phenotype prediction for mucopolysaccharidosis type I by in silico analysis

Li Ou et al. Orphanet J Rare Dis. .

Abstract

Background: Mucopolysaccharidosis type I (MPS I) is an autosomal recessive disease due to deficiency of α-L-iduronidase (IDUA), a lysosomal enzyme that degrades glycosaminoglycans (GAG) heparan and dermatan sulfate. To achieve optimal clinical outcomes, early and proper treatment is essential, which requires early diagnosis and phenotype severity prediction.

Results: To establish a genotype/phenotype correlation of MPS I disease, a combination of bioinformatics tools including SIFT, PolyPhen, I-Mutant, PROVEAN, PANTHER, SNPs&GO and PHD-SNP are utilized. Through analyzing single nucleotide polymorphisms (SNPs) by these in silico approaches, 28 out of 285 missense SNPs were predicted to be damaging. By integrating outcomes from these in silico approaches, a prediction algorithm (sensitivity 94%, specificity 80%) was thereby developed. Three dimensional structural analysis of 5 candidate SNPs (P533R, P496R, L346R, D349G, T374P) were performed by SWISS PDB viewer, which revealed specific structural changes responsible for the functional impacts of these SNPs. Additionally, SNPs in the untranslated region were analyzed by UTRscan and PolymiRTS. Moreover, by investigating known pathogenic mutations and relevant patient phenotypes in previous publications, phenotype severity (severe, intermediate or mild) of each mutation was deduced.

Conclusions: Collectively, these results identified potential candidate SNPs with functional significance for studying MPS I disease. This study also demonstrates the effectiveness, reliability and simplicity of these in silico approaches in addressing complexity of underlying genetic basis of MPS I disease. Further, a step-by-step guideline for phenotype prediction of MPS I disease is established, which can be broadly applied in other lysosomal diseases or genetic disorders.

Keywords: Genotype/phenotype correlation; In silico; Mucopolysaccharidosis; Single nucleotide polymorphism.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Superimposed structure of native protein with modeled mutant protein for D349G. a Overall structure of the superimposed model. Native protein in white (cartoon shape), mutant protein in green, wild type residue (Asp349) in red, and mutated residue (Gly349) in yellow. b close-up view of the superimpose model. Main protein backbone in white, wild type reside (Asp349) in red, mutated residue (Gly349) in yellow, a chloride anion in green
Fig. 2
Fig. 2
Close-up view of superimposed structure of native and mutant residues (a P496R; b P533R; c T374P; d L346R). The main protein core is shown in white color while the wild type and mutated residues are shown in red and yellow color, respectively
Fig. 3
Fig. 3
Step-by-step guideline for phenotype prediction by in silico analysis

References

    1. Hopwood JJ, Morris CP. The mucopolysaccharidoses. Diagnosis, molecular genetics and treatment. Mol Biol Med. 1990;7:381–404. - PubMed
    1. Dierenfeld AD, McEntee MF, Vogler CA, Vite CH, Chen AH, Passage M, et al. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med. 2010;2:60ra89. doi: 10.1126/scitranslmed.3001380. - DOI - PMC - PubMed
    1. Boelens JJ, Aldenhoven M, Purtill D, Ruggeri A, Defor T, Wynn R, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981–3987. doi: 10.1182/blood-2012-09-455238. - DOI - PMC - PubMed
    1. Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164–2172. doi: 10.1182/blood-2014-11-608075. - DOI - PubMed
    1. Sands MS, Vogler C, Kyle JW, Grubb JH, Levy B, Galvin N, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest. 1994;93:2324–2331. doi: 10.1172/JCI117237. - DOI - PMC - PubMed

Publication types

LinkOut - more resources